Joshua Moller
Research Subjects
Joshua Moller has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Aanal Bhatt
Ginkgo Bioworks, Inc, MA, USA
1 shared publication - Adam Rosenbaum
Ginkgo Bioworks Inc
1 shared publication - Alexander Smith
Ginkgo Bioworks Inc
1 shared publication Ameya Kulkarni
Duke University
1 shared publication- Ammar Arsiwala
Ginkgo Bioworks, Inc, MA, USA
1 shared publication - Antonín Dušek
UCT-Prague
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 22 February 2026
- Published by Taylor & Francis in mAbs
- Vol. 18 (1) , 2634216
2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization
Monoclonal antibodies (mAbs) are among the most successful therapeutic modalities, with over 200 marketed products and nearly 1400 candidates in clinical development.1 While high-affinity binding r...
- 22 February 2026
- Published by Taylor & Francis in mAbs
- Vol. 18 (1) , 2634216
Top Cited PapersOpen Access2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization
Monoclonal antibodies (mAbs) are among the most successful therapeutic modalities, with over 200 marketed products and nearly 1400 candidates in clinical development.1 While high-affinity binding r...
- Open Access
Guided Generation for Developable Antibodies
Therapeutic antibodies require not only high-affinity target engagement, but also favorable manufacturability, stability, and safety profiles for clinical effectiveness. These properties are collectively called `developability'. To enable a computational framework for optimizing antibody sequences for favorable developability, we introduce a guided discrete diffusion model trained on natural paired heavy- and light-chain sequences from the Observed Antibody Space (OAS) and quantitative developability measurements for 246 clinical-stage antibodies. To steer generation toward biophysically viable candidates, we integrate a Soft Value-based Decoding in Diffusion (SVDD) Module that biases sampling without compromising naturalness. In unconstrained sampling, our model reproduces global features of both the natural repertoire and approved therapeutics, and under SVDD guidance we achieve significant enrichment in predicted developability scores over unguided baselines. When combined with high-throughput developability assays, this framework enables an iterative, ML-driven pipeline for designing antibodies that satisfy binding and biophysical criteria in tandem.
Open AccessGuided Generation for Developable Antibodies
Therapeutic antibodies require not only high-affinity target engagement, but also favorable manufacturability, stability, and safety profiles for clinical effectiveness. These properties are collectively called `developability'. To enable a computational framework for optimizing antibody sequences for favorable developability, we introduce a guided discrete diffusion model trained on natural paired heavy- and light-chain sequences from the Observed Antibody Space (OAS) and quantitative developability measurements for 246 clinical-stage antibodies. To steer generation toward biophysically viable candidates, we integrate a Soft Value-based Decoding in Diffusion (SVDD) Module that biases sampling without compromising naturalness. In unconstrained sampling, our model reproduces global features of both the natural repertoire and approved therapeutics, and under SVDD guidance we achieve significant enrichment in predicted developability scores over unguided baselines. When combined with high-throughput developability assays, this framework enables an iterative, ML-driven pipeline for designing antibodies that satisfy binding and biophysical criteria in tandem.